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Summary
A cell adhesion model was previously used to select a series of monoclonal antibodies (mAbs),
which were subsequently found to recognize CD44/Pgp-1. Interest in these reagents increased
with the finding that they totally inhibited production of lymphoid or myeloid cellsin long-term
bone marrow cultures. Further investigation has now revealed that hyaluronate is a potential
ligand for CD44 and that hyaluronate recognition accounts for the adhesion between B lineage
hybridoma and stromal cells. The hybridoma cells adhered to hyaluronate-coated plastic wells
as well as to monolayers of stromal cells. The adhesion in both cases was inhibited by treatment
with hyaluronidases, and did not require divalent cations. Addition of exogenous hyaluronate
also diminishedbinding of lymphoid cells to stromal cells. One of several mAbs to Pgp-1/CD44
was particularly effective at blocking these interactions. Since hyaluronate and Pgp-1/CD44 were
present on both cell types, experiments were done to determine the cellular location ofinteracting
molecules required for the adhesion process. Treatment oflymphoid cells with an anti-Pgp-1/CD44
antibody was more inhibitory than antibody treatment ofthe stromal cells. Conversely, hyaluronidase
treatment of stromal cells reduced subsequent binding more than treatment of the lymphoid
cells. Adhesive interactions that involve hyaluronate and CD44 could contribute to a number
of cell recognition processes, including ones required for normal lympho-hemopoiesis.
T
he avid binding of a B lineage hybridoma to a cloned
stromal cell line recently permitted the selection of a new
panel ofmAbs based on their ability to inhibit this adhesion
(1). Several ofthese reagents also blocked lympho-hemopoiesis
when included in long-term bone marrow cultures, suggesting
that the molecule(s) they recognize has considerable func-
tional importance. Immunoprecipitation and other analyses
revealed that these antibodies identify epitopes on the Pgp-
1/CD44 glycoprotein (1). Molecular cloning was recently
achieved for human and murine Pgp-1/CD44 (2-5). Of par-
ticular interest was the finding that the NH2-terminal do-
main of this protein is homologous to link protein and the
core protein of large proteoglycans, both of which bind to
a glycosaminoglycan, hyaluronate. In addition, this domain
is highly conserved between humans and mice (4), suggest-
ing that hyaluronate might be a ligand for Pgp-1/CD44.
Hyaluronate is widely distributed in extracellular matrices
and has been implicated in a number ofbiological phenomena,
including cell-cell adhesion, cell migration, embryonic de-
velopment, and pathogenesis (6-8). A receptor for hyaluronate
has also been described that is similar to Pgp-1/CD44 with
respect to size, cellular representation, and interaction with
the cytoskeleton (7, 9-16). We now report that adhesive in-
teractionsbetween one lymphoid cell line and certain adherent
cell clones are totally dependent on hyaluronate and Pgp-
1/CD44. This mechanism of cell recognition could have
general importance because both molecules are widely dis-
tributed on hemopoietic and other tissues.
Materials and Methods
Cellsand Cell Cultures.
￿
The BMS2 stromal cell line was estab-
lished from bone marrow and has been extensively studied for its
ability to support growth of stromal cell-dependent lymphocyte
clones (17-20). Other adherent cell clones were isolated from ei-
ther bone marrow (BMSI) or spleen (SNS1, SS1) and share some
properties with BMS2 (17). BALB/3T3 and NIH/3T3 cells were
obtained through the American Type Culture Collection (ATCC,
Rockville, MD). BM-2 is a B cell hybridoma producing antiTNP
mAb. All of these lines were maintained in RPMI 1640 medium
supplemented with 10% FCS, 50 ;.M 2-ME and antibiotics.
Antibodies.
￿
The rat mAb IM 7.8.1 (anti-Pgp-1) (21) was kindly
provided by Dr. Ian S. Trowbridge (The Salk Institute, San Diego,
CA). Rat mAbs were prepared in our laboratory using the bone
marrow-derived stromal cell clone BMS2 as an immunogen (1).
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rine Pgp-1/CD44, and KMC 8.8 recognizes an unrelated antigen
(Miyake, K., unpublished observations). AllmAbs were semipurified
from ascitic fluids of SCID mice by ABx column chromatography
(jT. Baker Inc., Philipsburg, NJ).
Reagents and Hyaluronidase Treatment.
￿
Glycosaminoglycans were
obtained from thefollowingcommercial sources: hyaluronate, Sigma
Chemical Co., catalog no. H-4015 (St. Louis, MO); chondroitin
sulfate A (CalBiochem-Behring Corp., La Jolla, CA);chondroitin
sulfate C and heparansulfate(Seikagaku Kogyo Co., Tokyo,Japan);
heparin (Organon Inc., W Orange, NJ). For coating the tissue
culture dishes, these glycosaminoglycans were dissolved in PBS
(5 mg/ml), except heparin, which was used without dilution
(20,000 U/ml). Testicular hyaluronidase was obtained from Cal-
Biochem-Behring Corp. andStreptomyces hyaluronidase waspur-
chased from ICN Immunobiologicals (Lisle, IL). These were dis-
solved in HBSS andused at 5,000U/ml (testicular) and20 TRU/ml
(Streptomyces) finalconcentrations. Thebiotinylated proteoglycan
probe (b-PG) for staining hyaluronate was purified from cartilage
proteoglycan using the methods of Green et al. (10). BM-2 cells
(5 x 106/ml) were suspended in 10% FCS RPMI 1640 with
hyaluronidase for 1 hr at 37°C. Adherent cells were treated in the
culture wells (2 x 104/well) with the same concentration of
hyaluronidase as for BM-2 cells. When treated cells were subse-
quently stained with b-PG, no residual hyaluronate could be de-
tected, indicating that the conditions forenzymatic reaction were
appropriate (see below).
Detection ofMembrane-boundHyaluronate.
￿
Flow cytometry was
used to evaluate expression of hyaluronate on cell surfaces. BM-2
or BMS2 cells (5 x 106/ml) were suspended in 10% FCS RPMI
1640 and aliquots were treated with 5,000 U/ml of testicular
hyaluronidase for 1 hat 37°C. The suspensions were then incubated
for 20 minon icewith theb-PG probeat aconcentration of 1 Wg/ml
in RPMI 1640 containing 1% BSA and 0.1% sodium azide (10).
After thorough washing, the cells were incubated with FITC-
conjugated avidin (Zymed Laboratories, SanFrancisco, CA)foran
additional 20 min. Propidium iodide (Sigma Chemical Co.) was
added during thesecond incubation to excludedead cells. Labeled
cells were then analyzed on an EPICS V flow cytometer (Coulter
Electronics Inc., Hialeah, FL).
Cell Adhesion Assay.
￿
Bcell hybridoma BM-2 cellswere radio-
labeledby incubating 4 x 10' cells in 1 ml complete medium with
100 1ACi of Naz[S1Cr]04 for 1 h at 37°C and then washing three
times in complete medium. The labeled cells (2 x 101/well) were
added to 24-well plates (ComingGlass Works, Corning, NY).For
direct adhesion to glycosaminoglycans, the plates were precoated
with 5 mg/ml of the substances dissolved in PBS the day before
(22), and then washed three times with PBS immediately before
the addition of BM-2 cells. For BM-2 adhesion to adherent cells,
adherent cellswere plated (2 x 104/well) in complete medium and
allowed to grow overnight before the binding assay.
Forassessment of divalent cation requirements, HBSS wasused
supplemented with 10% FCS that had been dialyzed against PBS
without divalent cations. Cellswere washed in this medium three
times immediately before the adhesion assay and allpossible com-
binations of 0, 0.1, and 1.0 mM final concentrations ofCal` and
Mgz+ added at the same time as labeled BM-2 cells. The plates
were incubated for 1 h at 37°C, and unboundcells were removed
by three cycles of washing in prewarmed complete medium with
vigorous agitation on a Minishaker (Dynatech Laboratories Inc.,
Alexandria, Va) for 30 s before each aspiration. Bound cells were
lysed with 0.1 N NaOH, 1% NP-40 (Sigma Chemical Co.) and
the "Cr counted with a gamma counter (Beckman Instruments
70 Hyaluronate- and CD44-dependent Cell Adhesion
Inc., Fullerton, CA). Percentages of bound cells were determined
by theformula: percent bound - [(cpm from boundcells)/(input
cell associated cpm - spontaneously released cpm)] x 100.
Results
Adhesion of B Lineage Hybridoma Cells to Hyaluronate.
Hyaluronate can be coated on plastic dishes (22) and we ex-
ploited this to determine that lymphocytes maydirectly recog-
nize and adhere to this glycosaminoglycan. Of several sub-
stances that were tested, bindingwas only significant in wells
coated with hyaluronate (Table 1) . Attachment involved up
to 96% of the lymphocytes and was appreciable within 15
min of their addition to thecultureplates. This binding was
completely abolished when thecoated plates were pretreated
with Streptomyces hyaluronidase (data not shown). These
results suggested that hyaluronate might participate in adhe-
sion between two cell types such as stromal cells and lym-
phocytes. To determineif either ofthesecellsbear hyaluronate,
we used a biotinylated probe obtained from cartilage pro-
teoglycan (b-PG) which has been previously shown to bind
to hyaluronate with high affinity and specificity (10). Indeed,
flow cytometryrevealed measurable quantities of hyaluronate
on the BM-2 cells, as well as on a cloned stromal cell line
(Fig. 1). The specificity ofbindingwas confirmedby hyaluroni-
dase treatment.
Similarities between Binding ofLymphocytes to Stromal Cells
and Hyaluronate. We previously selected mAbs on thebasis
of their ability to inhibit recognition of cloned stromal cells
by the BM-2 lineage hybridoma (1). Immunochemical and
other analyses revealed that these antibodies detect epitopes
on the Pgp-1/CD44 glycoprotein. We therefore tested the
ability of the same antibodies to block adhesion of lympho-
cytes to hyaluronate coated culture wells (Table 2). Binding
wasvirtually abolishedby the KM 201 antibody and slight,
but consistent inhibition was observed with two other anti-
bodies that also recognize Pgp-1/CD44 (KM 703 and IM
Table 1.
￿
Adhesion ofB Lineage Hybridoma Cells to
The wells of plastic plates were coated with glycosaminoglycans and
radiolabeled BM-2 cells added. The results were presented as mean
values t SE for quadruplicate wells. Similar results were obtained in
two independent experiments . Prior treatment of hyaluronate-coated
wells with Streptomyces hyaluronidase completely abolished the
binding of BM-2 cells in this assay (data not shown).
Glycosaminoglycans
Coated with: Bound cpm Percent cells bound
None 425 ± 68 1.5 t 0.2
Hyaluronate 16,840 ± 677 63.4 ± 2.5
Chondroitin Sulfate A 576 ± 103 2.2 ± 0.4
Chondroitin Sulfate C 304 ± 12 1.1 ± 0.1
Heparan Sulfate 240 ± 21 0.9 t 0.1
Heparin 350 f 28 1.3 ± 0.1w d
p
I3
a
z
as
U
d
w
v
of
BM-2
Y
v
P
x
I
1
￿
10
￿
102 ￿10 3 1
￿
10
Fluorescence Intensity
7.8.1). It should be noted that KM 201 was also the most
effective of our anti Pgp-1/CD44 antibodies in blocking adhe-
sion oflymphocytes to stromal cells (reference 1, and see Table
6 below). A pool of purified normal rat IgG, or an antibody
that recognizes a different cell surface glycoprotein (KMC
8.8), had no effect. Adhesion of the BM-2 hybridoma cell
line to stromal cells or hyaluronate-coated dishes was not re-
markably dependent on divalent cations. Addition of 0.1 or
1.0 mM concentrations of Cat+ and/or Mgt+ to the assay did
not influence the numbers of cells that bound. Prewashing
of cells and dishes with 5 mM EDTA also had no effect on
the subsequent binding to hyaluronate-coated dishes (datanot
shown).
Hyaluronate Is an Important Mediator of B Cell Hybridoma
Adhesion to Stromal Cells. When added to the medium in
relatively high concentrations, hyaluronate inhibited the adhe-
sion of hybridoma cells to stromal cells (Fig. 2) . Similar
amounts of another glycosaminoglycan, chondroitin sulfate
A, had no effect. This result is consistent with the inability
oflymphocytes to bind to chondroitin sulfate-treated dishes
Table 2.
￿
Antibodies Block Adhesion ofHybridoma Cells to
Hwluronate
Hyaluronic acid (5 mg/ml) was coated on the bottom of plastic
wells, and radiolabeled BM-2 was added with the purified antibod-
ies. The values were presented as the means t SE for quadruplicate
wells, and the result was confirmed for reproducibility. Adhesion of
BM-2 cells to uncoated wells averaged 405 ± 90.
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BMS2
(Table 1) and suggests the selectivity ofbinding to hyaluronate.
Since the inhibition of cell-cell adhesion by exogenous hy-
aluronate was only partial, other ligands of CD44 might be
involved. Also, it was not clear from these results whether
stromal cell associated, or lymphocyte membrane-associated
hyaluronate was important for this interaction. To clarify these
issues, the two cell types were treated separately with hy-
aluronidase before the binding assay (Table 3). Treatment of
either the adherent stromal cell layer alone, or both the lym-
phocytes and stromal cells with enzyme prevented binding.
Either bovine testicularhyaluronidase (Exp. 1), or Streptomyces
hyalurolyticus (Exp. 2) derived enzymes were effective. Hr
aluronidase treatment had no effect on the density ofCD44
on lymphocytes (results not shown). Furthermore, neither
enzyme caused significant cell death, as assessed by chromium
release from labeled BM-2 cells or inspection of adherent layer
cells by phase-contrast microscopy (data not shown). There
was a small, but reproducible reduction in the extent ofbinding
when only the hybridoma cells were enzyme treated. These
Figure 1.
￿
Demonstration of
hyaluronate expression on stromal cells
and hybridoma cells by flow cytom-
etry. Cells (5 x 106/ml) were in-
cubated with or without testicular
hyaluronidase for 1 h at 37°C in
complete medium, and then stained
with a biotinylated proteoglycan
probe as previously described (10).
After washing three times, the cells
were visualized with FITC-labeled
avidin. Control profiles (dotted line)
show the background fluorescence of
cells that were stained with the
second reagent only.
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Figure 2.
￿
Inhibition of cell adhesion by addition of exogenous
glycosaminoglycans. BM-2 cells were added to monolayers of BMS2
along with the indicated amounts of hyaluronate or chondroitin
sulfate A. The results are presented as mean values t SE for tripli-
cate determinations.
mAb (5 Kg/ml) Bound cpm Percent cells bound m a
N
N
U
None 23,170 ± 980 45.3 ± 1 .9
Rat IgG 23,088 ± 608 45.2 ± 1 .2
V
KMC 8.8 22,350 t 1021 43.7 ± 2.0
a-
KM 201 441 ± 165 0.8 t 0.3
KM 703 15,160 ± 3605 29.7 ± 7.1
IM 7.8.1 17,844 ± 3184 34.9 ± 6 .2Table 3.
￿
Hyaluronidase Treatment Affects Interaction of
Hybridoma and Stromal Cells
- + 1,400±133 3.2±0.1
+
￿
+
￿
2,081 ± 40
￿
4.3 t 0.1
Radiolabeled BM-2 (5 x 106/ml) and BMS2 (2 x 104/well) cells
were treated with testicular hyaluronidase (5,000 U/ml) in Exp.1 or
Streptomyces hyaluronidase (20 TRU/ml) in Exp.2 for 1 h at 37°C,
and then used in the adhesion assay after washing three times in
complete medium. Treatment with these enzymes did not contribute
to spontaneous chromium release (data not shown) .
results strongly suggested that hyaluronate is a functional
ligand for recognition between these twocell types and that
hyaluronate associated with stromal cell membranes is par-
ticularly important. The receptor for hyaluronate might be
Pgp-1/CD44, which is well represented on the hybridoma
cells (1). Consistent with this interpretation, pretreatment
of hybridomacells with the KM 201 mAb was consistently
more effective than pretreatment of stromal cells (Table 4).
The inhibition was even higher when both cell types were
antibody treated, or when theantibody wascontinually present
in the culture medium.
Participation ofHyaluronate in Recognition Between OtherCell
Types. Both the cell surfaceglycoprotein Pgp-1/CD44 and
its putative ligand hyaluronate are widely distributed in var-
ious organs, and multiple adhesion mechanisms involving lym-
phocytes have previously been described (6, 7, 14-16). The
particular combination of BM-2 hybridomaandBMS2 stromal
cells might not be representative of binding between cells
taken from other tissues. Therefore, we used a panel of ad-
herent spleen-, embryo-, or bone marrow-derived stromal
cells to determine the relative importance of this particular
cell adhesion mechanism. A substantial fraction of theBM-2
cells bound to each of these types of adherent cells (Table
5) . However, hyaluronidasetreatment revealed marked differ-
ences in thedegree to which hyaluronate was involved. The
combination of BM-2 and BMS2 cells was most inhibited,
whereas the interaction between BM-2 cells and another
marrow-derived stromal cell clone, BMS1, was only slightly
affected. As might be predicted, the adhesion to BMS1 was
also relatively resistant to treatment with the KM 201 anti-
body (Table 6). In otherpreliminary experiments, thebinding
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Table 4.
￿
Pretreatment with Antibodies to Pgp-1/CD44 Affects
Interaction ofHybridoma and Stromal Cells
BM-2 hybridoma cells or adherent layers of BMS2 stromal cells were
treated separately with purified KM 201 antibodies (10 '~g/ml) in
complete medium for 30 min at 4°C and then washed three times
before use in the adhesion assay. The results are means t SE of
quadruplicate determinations. This experiment is representative of
three independent experiments.
of pre-B lymphoma cells to stromal cells was less avid than
observed with theBM-2 hybridoma (K.M., unpublished ob-
servations).
Theseresults suggest that multiple mechanisms can poten-
tially contribute to the binding strength betweenlymphoid
cells and fibroblast-like cells. One of these involves cell sur-
face hyaluronate and Pgp-1/CD44.
Discussion
The direct interaction between a glycosaminoglycan, hy-
aluronate, and the cell surface glycoprotein, Pgp-1/CD44,
accounts for most, if not all, of the binding between a B
Table 5.
￿
Differential Effects ofHyaluronidase Treatment on Other
Adherent Cell Lines
Percent cells bound
Radiolabeled BM-2 (5 x 106/ml) and adherent cell lines (2 x
104/well) were treated with testicular hyaluronidase (5,000 U/ml)
for 1 h at 37°C in complete medium. These cells were then used in
the adhesion assay after washing three times. The results are pre-
sented as mean values ± SE for quadruplicate determinations.
Hyaluronidase
treatment
KM 201
pretreatment
Percent cells Percent
Exp. BM-2 BMS2 Bound cPM Percent cells bound BM-2 BMS2 Bound cpm bound inhibition
1 - - 34,815 ± 437 84.9 ± 1.1 - - 23,120 ± 856 51.6 ± 2.1 -
+ - 20,719 ± 1385 54.7 ± 3.7 + - 9,586 ± 338 23.2 ± 0.8 55.0
- + 473±47 1.2±0.1 - + 17,505 t 1229 42.4 ± 3.0 17.8
+ + 528±48 1.4±0.1 + + 6,195 ± 202 15.0 ± 0.5 70.9
Continuous Addition 2,457 ± 89 5.9 ± 0.2 88.6
2 - - 38,718 ± 376 89.1 ± 0.1
+ - 30,090 ± 402 62.9 ± 0.1
Adherent cell No treatment Hyaluronidase
Percent
inhibition
BMS1 79.1 ± 1.1 66.0 ± 3.1 16 .6
BMS2 81 .5 ± 1.0 7.1 ± 0.1 91 .3
SS1 80.7 ± 1.3 50.0 ± 0.5 38 .0
SNS1 59.4 ± 1.0 38 .3 ± 2.2 35 .5
NlH/3T3 85.6 ± 1.3 17 .5 ± 0.7 80.0
BALB/3T3 80.4 ± 1.6 10.4 ± 0.8 87.1lineage hybridoma and a bone marrow-derived stromal cell
line. The hybridoma quickly attached to hyaluronate-coated
plastic dishes and this binding was abolished by a mAb to
Pgp-1/CD44. Furthermore, the adhesion of hybridoma to
cloned stromal cells was blocked by hyaluronidase treatment,
exogenous hyaluronate, or the mAb. Finally, the binding medi-
ated by these two cell-associated molecules was independent
of divalent cations, as has been previously described for a
hyaluronate receptor (23). These findings suggest one pos-
sible mechanism for cell-cell recognition.
The Pgp-1/CD44 molecule has been independently detected
in multiple species and in association with a variety of bio-
logical phenomena (see reference 16 for a review). CD44 was
originally described as a membrane glycoprotein on human
T cells (24) and the murine homologue (Pgp-1) first derived
from a study of membrane glycoproteins on 3T3 cells (25).
Subsequent studies revealed a broad tissue distribution and
some size heterogeneity of this molecule (14-16). In mice,
Pgp-1/CD44 expression has been correlated with maturation
and function of T lymphocytes (26). A subset of antibodies
to human CD44 blockinteraction of lymphocytes with high
endothelial venules (27), and at least some ofthese glycopro-
teins act as receptors for extracellular matrix proteins (28).
Of particular relevance to this study was the recent finding
that Pgp-1/CD44 has an NH2-terminal domain with struc-
tural features of link protein and the core proteins of large
proteoglycans, both of which can bind to hyaluronate (22).
Treatment with anti-Pgp-1/CD44 mAbs or hyaluronidase,
as well as addition ofexogenous hyaluronate, inhibited binding
between BM-2 hybridoma and BMS2 stromal cells. Thus,
both Pgp-1 and hyaluronate seem to participate in the adhe-
sion phenomenon. Both cell types used in our adhesion model
express hyaluronate, as well as Pgp-1/CD44 (reference 1 and
Fig. 1). However, separate antibody treatment of BM-2 cells
was more effective than treatment ofBMS2 cells in reducing
binding in the adhesion assay (Table 4). The reciprocal result
was consistently obtained by separate hyaluronidase treatment
of these two cell types. That is, enzyme treatment of BMS2
cells influenced binding more dramatically than treatment
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Adherent cell lines were placed in 24-well plates (2 x 104/well) 1 d before assay. Radiolabeled BM-2 were added with the indicated antibod-
ies (10 hg/ml) and washed out after 30 min incubation at 37°C. Results are presented as mean values ± SE for quadruplicate determinations.
of BM-2 cells (Table 3). However, immunochemical studies
of Pgp-1/CD44 extracted from the two cell types did not
reveal obvious structural differences (reference 1 and Miyake,
K., unpublished observations).
A simple interpretation ofour findings is that Pgp-l/CD44
on our B lineage hybridoma cells recognizes and directly binds
to hyaluronate on the BMS2 stromal cell line. Binding of
BM-2 cells to hyaluronate-coated plates is consistent with this
notion, as are recent findings that certain other Pgp-1/CD44-
bearing cells adhere to such dishes, bind fluorescein-labeled
hyaluronate, or are agglutinated by it. All of these interac-
tions were inhibitable by anti-Pgp-1/CD44 antibodies (29).
Furthermore, the previously described hyaluronate receptor
is similar in size, divalent cation independence, and distribu-
tion to Pgp-1/CD44 (6, 7, 9-15, 23), suggesting that the
two are either closely related or identical. Indeed, one mAb
to Pgp-1/CD44, KM 201, completelyblocked binding of ra-
diolabeled hyaluronate to the hyaluronate receptor on SV
3T3 cells (Underhill, C.B., unpublished observations).
It is important to stress that other interpretations of these
findings are possible. For example, Pgp-1/CD44+ cells might
interact with Pgp-1/CD44+ cells via a low affinity, homo-
typic interaction that is stabilized by hyaluronate. Another,
more complex explanation would be that the link protein-like
domain of Pgp-1/CD44 stabilizes interactions between
hyaluronate and other glycosaminoglycans. Chondroitin sulfate
is covalently attached to some isoforms of Pgp-1/CD44 (30).
However, we found no evidence for participation of chon-
droitin sulfate in our adhesion assay (Table 1 and Fig. 2). Fur-
thermore, the binding was completely inhibited by Strep-
tomyces hyaluronidase, which is thought to be highly specific
for hyaluronate (31) . Our findings also do not exclude the
possibility that in some circumstances hyaluronate and Pgp-
1/CD44 might interact with each other on the same cell
surface.
In addition to hyaluronate, there are probably other ligands
for Pgp-1/CD44, including an endothelial cell glycoprotein
and certain forms of collagen (14, 28). Other well studied
adhesion molecules are known to have multiple ligands
Table 6. Contribution of Pgp-1/CD44 to Binding of Hybridoma Cells to
Percent cells bound
Other Adherent Cell
with the following
Lines
antibodies:
Adherent cell None Rat IgG KM 201 IM 7.8.1 KM 703
BMS1 51.4 ± 1.5 50.3 ± 1 .7 27.0 ± 0.3 42.9 ± 1 .2 52.0 ± 2.4
BMS2 35.2 ± 0.7 31.4 ± 0.3 7.7 ± 0.5 22.1 ± 0.6 23.4 ± 1 .3
SS1 40.9±1.9 36.9±2.8 12.1 ± 0.8 27.9 ± 1 .8 31.9 ± 0.3
SNS1 40.8±2.6 38.4±1 .7 12.7 ± 0.6 22.0 ± 1 .0 29.1 ± 1 .8
NIH/3T3 34.5 ± 0.7 32.1 ± 1 .1 9.7 ± 0.8 21.4 ± 1 .2 25.2 ± 2 .1
BALB/3T3 51 .1 ± 1.1 50.5 ± 2.1 12.0 ± 0.3 31.5 ± 1 .0 37.4 ± 1.1(32-34). Moreover, a recent study revealed that some Pgp-
1/CD44-bearing hemopoietic cells do not bind to hyaluronate
(29). It is as yet unclear if different transcription products
and/or postsynthetic modifications will correspond to different
binding specificities of this molecule. Alternatively, compe-
tition between ligands and differences in their availability might
govern the outcome of interactions with Pgp-1/CD44. We
and others have prepared panels of mAbs to this glycopro-
tein and the unique epitopes they recognize may be instruc-
tive in this regard. The KM 201 antibody was a potent in-
hibitor in the cell adhesion experiments described in this report
(Table 2 and reference 1), and might preferentially interact
with a putative hyaluronate binding domain ofPgp-1/CD44.
Mechanisms responsible for holding the various types of
hemopoietic cells in close association with the inductive mi-
croenvironment are potentially complex and a number of
candidate molecules have been identified (35-39). Our results
show that adhesion of the B cell hybridoma was not limited
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to bone marrow-derived stromal cell clones but also occurred
with adherent cell lines derived from spleen or embryos (Table
6) . Interactions with some of these cellswere relativelyresis-
tant to Pgp-1/CD44 antibody or hyaluronidase treatment,
suggesting that additional adhesion mechanisms are involved.
Also, it has previouslybeen found that some of the lymphoid
cells detach from the adherent layers oflong-term bone marrow
cultures after treatment with chelating agents or phospha-
tidylinositol-specific phospholipase C (40 and Kincade, P.W,
unpublished observations) . Neither of these results are con-
sistent with Pgp-1/CD44-hyaluronate-mediated adhesion.
Thus, while adhesion mediated by these two molecules might
be very important to hemopoiesis and other functions, it is
likely that other mechanisms contribute to the specificity and
degree of binding required for development and cell migra-
tion. It is important to determine the molecular basisof these
critical cell recognition processes and determine how each
is used and modulated in discrete sites.
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